PG001
Liraglutide biosimilar
Pipeline
Obesity and Diabetes
Liraglutide
Liraglutide
Biosimilar
Global No.1 Obesity and Diabetes Treatment
Features
Obesity and diabetes treatment administered once daily
-
Maintaining blood sugar through regulation of insulin and glucagon secretion
-
Weight loss by suppressing appetite through nervous system
Originator
Mechanism
Liraglutide’s core mechanism of action
It’s an analog of GLP-1(glucagon-like peptide-1) and activated the gastrointestinal hormone ‘incretin’ to control blood sugar levels and reduce weight
Obesity
Liraglutide delays the rate at which food is expelled from the stomach and acts on the appetite center to suppress appetite and increase satiety, thereby reducing the amount of food consumed and resulting in weight loss
Diabetes
Liraglutide regulates blood sugar by stimulating pancreatic beta cells to increase insulin secretion and inhibiting glucagon secretion
Equivalence analysis results
Liraglutide biosimilar research and development results
As a result of the development of a Liraglutide biosimilar, PEPGENE has completed the development of a biosimilar that is more than 99% similar to the original semaglutide